Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors.

The application of unrelated donor hematopoietic cell transplantation can be expanded with the use of mismatched donors if human leukocyte antigen (HLA) disparity does not lead to increased morbidity and mortality. The rules that govern permissibility of HLA mismatches are not well defined. The International Histocompatibility Working Group in hematopoietic cell transplantation measured the risks associated with locus-specific disparity in 4796 patients transplanted for low, intermediate, or high-risk hematologic diseases. The permissibility of a given HLA mismatch is in part defined by the locus and by disease risk.

[1]  N. Kröger,et al.  Isolated HLA-C mismatches in unrelated donor transplantation for CML , 2004, Bone Marrow Transplantation.

[2]  J. McCluskey,et al.  Matching for HLA DPA1 and DPB1 alleles in unrelated bone marrow transplantation. , 1999, Human immunology.

[3]  Anajane G. Smith,et al.  The biological significance of HLA‐DP gene variation in haematopoietic cell transplantation , 2001, British journal of haematology.

[4]  Anajane G. Smith,et al.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.

[5]  C. Brautbar,et al.  Bone marrow transplantation using unrelated and family related donors: the impact of HLA-C disparity. , 1996, Bone marrow transplantation.

[6]  M. Malkki,et al.  Effect of HLA-A2 allele disparity on clinical outcome in hematopoietic cell transplantation from unrelated donors. , 2007, Tissue antigens.

[7]  N. Russell,et al.  HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. , 2006, Blood.

[8]  B. Storer,et al.  Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. , 2001, The New England journal of medicine.

[9]  Takato O. Yoshida,et al.  EFFECT OF MATCHING OF CLASS I HLA ALLELES ON CLINICAL OUTCOME AFTER TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS FROM AN UNRELATED DONOR , 1998 .

[10]  D. Speiser,et al.  High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. , 1996, Blood.

[11]  Harriet Noreen,et al.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. , 2004, Blood.

[12]  B. Shaw,et al.  Clinical importance of HLA-DPB1 in haematopoietic cell transplantation. , 2007, Tissue antigens.

[13]  R. Tamouza,et al.  DPB1 disparities contribute to severe GVHD and reduced patient survival after unrelated donor bone marrow transplantation , 2002, Bone Marrow Transplantation.

[14]  M. Remberger,et al.  Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. , 2003, Tissue antigens.

[15]  H. Inoko,et al.  The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. , 2002, Blood.

[16]  Effie W Petersdorf,et al.  Limits of HLA mismatching in unrelated hematopoietic cell transplantation. , 2004, Blood.

[17]  A. Nademanee,et al.  Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. , 2001, Blood.

[18]  M. Chopek,et al.  The extent of HLA class II allele level disparity in unrelated bone marrow transplantation: analysis of 1259 National Marrow Donor Program donor–recipient pairs , 2000, Bone Marrow Transplantation.